Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | TLR3 | O15455 | 1/20 | 0.41 |
| ▸ | TLR5 | O60602 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.41 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.41 |
| ▸ | PNCK | Q6P2M8 | 1/20 | 0.41 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.41 |
| ▸ | CAMK1G | Q96NX5 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.40 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283534 | 0.88 | DRD3 (0.53) | ACSS2TLR4TLR3TLR5TLR2 | |
| SCHEMBL1283276 | 0.87 | DRD2 (0.50) | ACSS2MAPTDRD2DRD3TP53 | |
| SCHEMBL1283484 | 0.85 | TP53 (0.47) | ACSS2TLR7PLK1PLK3PLK2 | |
| SCHEMBL1282989 | 0.80 | PIN1 (0.55) | MAPTDRD2DRD3TP53LMNA | |
| SCHEMBL1283532 | 0.77 | TP53 (0.48) | ACSS2MAPTDRD2DRD3TP53 | |
| SCHEMBL1283440 | 0.77 | DRD3 (0.46) | MAPTDRD2DRD3HRH3 | |
| SCHEMBL1615416 | 0.76 | DRD3 (0.58) | ACSS2DRD2DRD3TP53HRH3 | |
| SCHEMBL1283543 | 0.75 | DRD3 (0.68) | ACSS2DRD2DRD3HRH3 | |
| SCHEMBL1283554 | 0.75 | PIN1 (0.53) | ACSS2MAPTDRD2DRD3TP53 | |
| SCHEMBL1283760 | 0.75 | DRD3 (0.59) | ACSS2DRD2DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ACSS2 2824/4885TLR4 105/4885TLR3 485/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ACSS2 2898/4885TLR4 80/4885TLR3 393/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | ACSS2 2898/4885TLR4 80/4885TLR3 393/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ACSS2 2898/4885TLR4 80/4885TLR3 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.